Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2018Current Hypertension Reviews

Cardiovascular Effects of Liraglutide

View Full Paper
Ask AI
Bookmark
Share

Key result

Liraglutide reduces major cardiovascular events ~13% compared to placebo.

  • HR 0.87
  • 95% CI 0.78-0.97
  • n=9,340

Why the study?

The cardiovascular effects of liraglutide, including macrovascular and microvascular events, heart failure use, and effects on heart rate and blood pressure, required comprehensive review.

Does liraglutide reduce cardiovascular events in patients with advanced type 2 diabetes and high baseline cardiovascular risk?

Population

9,340 patients with advanced type 2 diabetes and high baseline cardiovascular risk

Comparison

Liraglutide vs placebo

Design

Review including randomized LEADER trial

Follow-up

Median 3.8 years

Authors

NMNasser E. Mikhail

Discussion

Loading...

Member takes

Overview

Liraglutide CV effects in advanced T2D warrant ongoing monitoring; leaves open dedicated HF and microvascular outcome trials.

Structured PICO

Does liraglutide reduce cardiovascular events in patients with advanced type 2 diabetes and high baseline cardiovascular risk?

P
Population
9,340 patients with advanced type 2 diabetes and high baseline cardiovascular risk, followed for a median of 3.8 years.
I
Intervention
Liraglutide
C
Comparator
Placebo
O
Outcome
First occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal strokecomposite

Main Result

Hazard Ratio: 0.87 (95% CI 0.78–0.97)

Liraglutide reduces major adverse cardiovascular events in patients with advanced type 2 diabetes and high cardiovascular risk, but may be harmful in those with severe heart failure.

Limitations

  • May be harmful in patients with severe heart failure, in part due to an increase in heart rate.
  • Further studies are needed to evaluate long-term effects and efficacy in patients with low cardiac risk.
  • Lack of data on long-term effects of liraglutide
  • Unclear if beneficial effects extend to patients with type 2 diabetes and low cardiac risk

Cite This Study

Nasser E. Mikhail (2018) conducted a review in Advanced type 2 diabetes and high baseline cardiovascular risk (n=9,340). Liraglutide vs. Placebo was evaluated on First occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke (HR 0.87, 95% CI 0.78-0.97). Liraglutide significantly reduced the composite primary outcome of cardiovascular death, non-fatal MI, or non-fatal stroke compared to placebo (HR 0.87; 95% CI 0.78-0.97).

synapsesocial.com/papers/6ab4cbdd7fc930a00ef644b7https://doi.org/10.2174/1573402114666180507152620
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)—a multicentre, double‐blind, randomised, placebo‐controlled trial2016 · 588 citations
  2. 2Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease2017 · 42 citations
  3. 3Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes2014 · 172 citations
  4. 4Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction2016 · 703 citations
  5. 5Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes2016 · 6,919 citations